Isodiol International Inc. just signed a letter of intent to supply cannabidiol (CBD) to Zenabis Ltd. The company will provide CBD isolate to Zenabis from its subsidiary, BSPG Laboratories, in the United Kingdom (UK).
Isodiol subsidiary BSPG recently received government approval from UK’s Medicines and Healthcare Products Regulatory Agency (MHRA). The approval gives Isodiol the ability to manufacture and export CBD to global markets from the UK.
Isodiol believes it is the first company in the industry to receive MHRA approval for a CBD-related product. The approval sets Isodiol apart from all other CBD companies worldwide. It positions Isodiol as a secure and reliable supplier that can serve the newly created demand for CBD drug development. The validation will push research, clinical studies, and clinical trials to create innovative CBD solutions.
Zenabis is a biopharmaceutical company that is on its way to becoming one of the largest cannabis producers in Canada. The Zenabis team has experience of working with low-cost, large-scale production. The team consists of experts in facility management, pharmaceuticals, cultivation, and sustainability. The company also conducts research on medical cannabis.
Isodiol CEO Marcos Agramont is pleased with the supply agreement for its pharmaceutical-grade CBD isolate. The team is also excited to partake in Zenabis’s research and development on the medicinal compound.
Kevin Coft, the CEO of Zenabis, is also excited to be on board with Isodiol. He looks forward to working with the company to develop new drugs and improve lives all over the world. The merger gives the two companies the opportunity to conduct more trials and prove the efficacy of CBD.
If initial import and product testing are successful, Isodiol and Zenabis intend to execute a definitive supply agreement and expand their scope of collaboration.
About Isodiol International Inc.
Isodiol is a market leader in pharmaceutical-grade phytochemical compounds and an industry leader in the development of CBD consumer products. It is one of the pioneers in the commercialization of 99%+ pure cannabinoids, microencapsulation, and nanotechnology. The company manufactures the highest-quality consumable and topical products for skin care and pain management. Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs and the expansion of its phytoceutical portfolio. Besides this, the company plans to aggressively expand into international markets like Latin America, Asia, and Europe.